-
1 Comment
Carmat SA is currently in a long term downtrend where the price is trading 9.1% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Carmat SA's total revenue sank by 0.0% to $346K since the same quarter in the previous year.
Its net income has dropped by 0.0% to $-9M since the same quarter in the previous year.
Finally, its free cash flow fell by 45.5% to $-13M since the same quarter in the previous year.
Based on the above factors, Carmat SA gets an overall score of 1/5.
| ISIN | FR0010907956 |
|---|---|
| Sector | Healthcare |
| Industry | Medical Devices |
| Exchange | F |
| CurrencyCode | EUR |
| Target Price | None |
|---|---|
| Beta | 1.52 |
| Market Cap | 53M |
| PE Ratio | None |
| Dividend Yield | None |
Carmat SA designs and develops total artificial heart for people suffering from end-stage biventricular heart failure in France and internationally. Its product includes Aeson, an active implantable medical device intended to replace the ventricles of the native heart in patients suffering from advanced heart failure. The company was incorporated in 2008 and is headquartered in Vélizy-Villacoublay, France.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for CXT.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
